NEW YORK, May 3 – Zymark and Qiagen have agreed to develop and launch ultra high-throughput nucleic acid handling automation systems that will combine the two companies’ products, the companies said Thursday.
Zymark of Hopkinton, Mass. manufactures laboratory automation and robotic systems for life sciences customers.
The joint effort will combine Qiagen’s BioRobot platforms with Zymark’s RapidPlate 96/384 Microplate Pipetting Workstation, Staccato workstations, and Twister Universal Microplate Handler.
"The alliance with Zymark expands the reach of our nucleic acid handling, separation, and purification technologies into the highest throughput environments in genomics by leveraging on Zymark's remarkable laboratory integration technologies," Qiagen CEO Metin Colpan said in a statement.
Qiagen, a Netherlands holding company, supplies products for the separation, purification, and handling of nucleic acids. Over the last year, the company has signed on to joint ventures and licensing agreements with Agilent Technologies, Japan’s Daiichi Pharmaceutical subsidiary of Daiichi Pure Chemicals, the University of Washington School of Pharmacy, Zeptosens AG of Germany, Becton, Dickinson, and Luminex.
In April, Qiagen acquired Japanese nucleic acid maker Sawady. The company has also recently acquired Operon Technologies and Rapigene, now renamed Qiagen Genomics